Description

Pramipexol-ZN (pramipexole) tablets 1 mg. № 30

Ingredients:

Each tablet contains 1 mg of pramipexole.

Dosage:

The recommended dosage is determined by a healthcare provider based on individual needs. It is typically started at a low dose and gradually increased to achieve the desired therapeutic effect.

Indications:

Pramipexol-ZN is indicated for the treatment of Parkinson’s disease and restless legs syndrome. It works by helping to restore the balance of dopamine in the brain, thereby improving motor function in Parkinson’s disease and reducing the symptoms of restless legs syndrome.

Contraindications:

Do not use Pramipexol-ZN if you are allergic to pramipexole or any other ingredients in the tablets. It is important to inform your healthcare provider about any medical conditions or medications you are taking before starting Pramipexol-ZN.

Directions:

Take Pramipexol-ZN exactly as prescribed by your doctor. The tablets are usually taken orally once daily, with or without food. It is important not to crush or chew the tablets.

Scientific Evidence:

Pramipexole, the active ingredient in Pramipexol-ZN, has been extensively studied for its efficacy in the treatment of Parkinson’s disease and restless legs syndrome. Research published in the Journal of Neurology has shown that pramipexole is effective in improving motor symptoms and quality of life in patients with Parkinson’s disease.

Additional Information:

In clinical trials, Pramipexol-ZN has demonstrated a favorable safety profile and tolerability. Common side effects may include nausea, dizziness, and fatigue. It is important to report any unusual symptoms to your healthcare provider.

Pharmacological Effects:

Pramipexole is a dopamine agonist that acts on dopamine receptors in the brain. By stimulating these receptors, pramipexole helps to mimic the effects of dopamine, a neurotransmitter involved in controlling movement and emotions. This action helps to alleviate the symptoms of Parkinson’s disease and restless legs syndrome.

Clinical Trials and Comparative Effectiveness:

Clinical trials have shown that pramipexole is effective in improving motor function and reducing symptoms in patients with Parkinson’s disease compared to placebo. Additionally, pramipexole has been found to be comparable in efficacy to other dopamine agonists used in the treatment of restless legs syndrome.

Overall, Pramipexol-ZN (pramipexole) tablets 1 mg. № 30 offer a well-established treatment option for Parkinson’s disease and restless legs syndrome, supported by scientific evidence and clinical trials.